KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 63 filers reported holding KINNATE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $379 | -51.5% | 125,000 | 0.0% | 0.01% | -73.9% |
| Q1 2023 | $781 | +2.4% | 125,000 | 0.0% | 0.05% | +7.0% |
| Q4 2022 | $763 | -99.9% | 125,000 | 0.0% | 0.04% | -32.8% |
| Q3 2022 | $1,494,000 | -5.2% | 125,000 | 0.0% | 0.06% | -23.8% |
| Q2 2022 | $1,576,000 | +11.9% | 125,000 | 0.0% | 0.08% | +42.4% |
| Q1 2022 | $1,408,000 | -36.4% | 125,000 | 0.0% | 0.06% | -1.7% |
| Q4 2021 | $2,215,000 | -23.0% | 125,000 | 0.0% | 0.06% | -6.2% |
| Q3 2021 | $2,878,000 | -1.1% | 125,000 | 0.0% | 0.06% | +8.5% |
| Q2 2021 | $2,910,000 | -25.3% | 125,000 | 0.0% | 0.06% | -14.5% |
| Q1 2021 | $3,895,000 | -21.7% | 125,000 | 0.0% | 0.07% | -35.5% |
| Q4 2020 | $4,973,000 | – | 125,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |